Corcept Therapeutics announced it has initiated MONARCH, a Phase 2b trial of its proprietary selective cortisol modulator miricorilant in patients with non-alcoholic steatohepatitis, or NASH. MONARCH is a 150-patient, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of miricorilant in adult patients with biopsy-confirmed NASH. Patients will receive either 100 mg of miricorilant or placebo orally twice weekly for 48 weeks. The primary endpoint is reduction in liver fat, with NASH resolution and fibrosis improvement as key secondary endpoints.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CORT:
- Corcept Initiates MONARCH – A Phase 2b Trial in Non-Alcoholic Steatohepatitis (NASH)
- Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Therapeutics price target raised to $35 from $31 at Piper Sandler
- Corcept Therapeutics weakness a buying opportunity, says Canaccord
- Corcept Therapeutics should be bought amid weakness, says Canaccord